(thirdQuint)BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose.

 Phase A (3 arm parallel group): All patients randomized during the BEYOND study (Bayer 306440) to either IFNB 1b group (250 mu g or 500 mu g) will continue their previously assigned study medication, applying the same level of blinding as during the BEYOND study, All patients randomized during the BEYOND study to Copaxone and all patients with premature discontinuation of study medication during the BEYOND study will receive open-label IFNB 1b 250 mu g.

 Phase B (single arm): All patients will receive open-label IFNB 1b 500 mu g) Randomization: No randomization in this trial, patient's allocation in this follow-up study depends only on prior trial groups.

 The preceding study was randomized.

 The trial is sponsored by Bayer Schering Pharma AG, Germany, Bayer HealthCare and Bayer HealthCare Pharmaceuticals Inc.

 Secondary outcome measure "Assessment of patient-reported outcomes (FAMS and EQ 5D: The variables FAMS and EQ-5D were not analyzed due to the termination of the study before start of Phase B.

.

 BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose@highlight

The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500 mu g dose of interferon beta (IFNB) 1b and will further investigate the safety and tolerability profile of interferon beta 1b 500 mu g during longer-term treatment.

